

第62回 日本公衆衛生学会 総会「感染症フォーラム」

感染症予防と健康危機管理

—SARS対策に学ぶこれからの感染症対策—

〈緊急付録：高病原性鳥インフルエンザ防疫マニュアル〉

監修 日本公衆衛生学会
発行 財団法人日本公衆衛生協会

目 次

I	ごあいさつ	1
	日本公衆衛生学会 理事長 多田羅浩三	
II	フォーラムの趣旨と進め方	2
	滋賀県長浜保健所長 角野 文彦 山形県村山保健所長 阿彦 忠之	
III	基調講演	3
	感染症対策の充実に向けて、今何が求められているか －SARS 制圧対策を振り返って－	
	WHO 西太平洋地域事務局長 尾身 茂	
IV	現地報告	15
	香港における SARS 疫学調査の現場からの報告	
	国立感染症研究所 感染症情報センター主任研究官 砂川 富正	
V	テーマ別討論	22
	1. 検疫所の役割と課題	22
	関西空港検疫所 丸山 浩 厚生労働省 藤崎 清道	
	2. 臨床現場の役割と課題	31
	日本医師会 雪下 國雄 泉佐野病院 中埜 肅	
	3. 公衆衛生機関の役割と課題	39
	厚生労働省 藤崎 清道 大阪府 土生川 洋 堺市保健所 安井 良則 香川県小豆保健所 久保 訓子 埼玉県衛生研究所 丹野瑳喜子 国立感染症研究所 岡部 信彦 広島大学 吉澤 浩司	
	4. 情報共有に関する課題	61
	産経新聞社 木村 良一 慶應義塾大学 青木 節子	
VI	総合討論とまとめ	67
	《SARS 対策に関する厚生労働省資料》	
	1. 今冬の SARS 対策について	73
	2. 今冬のインフルエンザ総合対策について	80
	《緊急付録：高病原性鳥インフルエンザ防疫マニュアル》	83

4. 情報共有に関する課題

司会者 角野

ありがとうございました。ここで討論の予定でしたが時間の関係で、次の「情報共有に関する課題について」指定発言をお二人から受けた後に、討論に移りたいと思います。それでは産経新聞社の木村さんからお願いいたします。

木村

私は現在、厚生労働省の記者クラブに籍を置いて取材活動をしている産経新聞社東京本社社会部の記者です。観光旅行で来日した台湾人医師の問題が、今回、私に与えられた「情報共有に関する課題」というテーマを語るうえで、最適な事例だと思いますので、ある程度この台湾人医師の問題に沿って話しを進めていきます。

台湾人医師の問題では①厚労省や大阪府などの地方自治体が、混乱から情報を確認するのに手間がかかり過ぎた②台湾人医師は入国時に発熱がなく、空港検疫の赤外線サーモグラフィーにひっかからず、帰国時には解熱剤を使用し、台湾の検疫も通過してしまい、水際作戦の限界が指摘された③台湾人医師は SARS 患者を治療した経緯があり、医師の病院では院内感染を起こしている。それを承知のうえで来日するという医師のモラルの欠如。以上の3点が指摘されました。それでも、厚生労働省は地方自治体の協力を得て、台湾人医師が来日後、どこのホテルに宿泊し、どんな交通機関を利用したかなど、詳細な情報を報道機関に提供して「発熱、せき、呼吸困難の症状がある場合、あるいは心配な場合は、保健所に相談してください」と呼びかけました。それとともに台湾人医師と接触した可能性のある人の追跡調査も行いました。前に述

べた混乱や情報公開までの迅速さは別として、それなりに評価のできる対応だったと思っています。

しかし、この詳細な情報提供の結果、風評被害や不安が広がりました。台湾人医師が宿泊したホテルは予約のキャンセルが相次ぎ、自主休業に追い込まれました。白い防護服で身を固めた保健所の職員が航空会社のカウンターや観光地の階段の手すりを消毒して回るといった過剰な反応もありました。厚生労働省がインターネット上などで「SARS 患者が使用した旅館やホテル、レストランを利用することに問題はありませぬ」と呼びかけても、こうした不安や風評被害はなかなか、収まりませんでした。

しかし、情報を公開しないと、「本当に大丈夫なのか」と騒ぎは大きくなるばかりで、公開すると今度は過剰反応を起こす。情報はどこまで、どういう形で、どの時点で、公開したらいいのでしょうか。行政機関としては、ジレンマに落ち入ることでしょう。

新聞社の立場から言わせていただければ、基本的にすべての情報をできるだけすみやかに、そして正確に出してもらいたいと考えています。行政機関から出された情報をニュースとしてどんな形でどこまで出すかは、新聞社に任せてほしいと思うのです。なぜならば、報道したニュースの内容に対する責任は、新聞社がとるのが当然だからです。

そうは言っても、「厚生労働省によると」とか「大阪府は」とか「〇〇保健所は」という表現で報道される以上、ニュースソースは明らかであり、情報を出す行政機関にもその情報に対する責任はどうしても発生します。それに、報道といっても、スポーツ新聞や週刊誌、テレビのワイドショーもあり、「おもしろければそれで良

い」「視聴率や販売部数さえ上がれば OK」という報道姿勢があるのも事実です。

それでは SARS における情報共有では、どうしたら余計な不安や風評被害を出さずに済ませることができるのでしょうか。

一番大切なのは、国民に SARS に対する正確な知識を持たせることです。たとえば、予防にしてもその基本は、過労を避け、十分な睡眠と栄養バランスのある食事をとり、さらにウイルスの付着した手で、口や鼻を触って感染するのを防ぐため、手洗いをよくする。これだけでも、かなりの予防になると思います。SARS だけではなく、インフルエンザや他の感染症の予防にもなります。台湾人医師が宿泊したホテルや旅館にキャンセルが相次いだことを考えると、SARS ウイルスは便の中では 3 時間から 4 日間生き、机の上など乾燥した環境下では、そう何日間も生きていないといった知識も、国民にきちんと伝えておくことが大切でしょう。

次に重要なことは、情報を出せば、それなりの風評被害は出るとの認識を持つておくことです。その風評被害に行政として何らかの補償制度を設けることができれば、それに越したことはないと思います。転ばぬ先の杖でしょうか。

かつてなことばかり、申し上げてきましたが、風評被害や不安の広がりを感じて情報を隠すことだけは、避けなければなりません。なぜならば、中国（香港を除く）は、情報を隠したばかりに感染者 5,300 人以上、死者約 350 人という数字を記録したばかりではなく、香港を経由して世界各国に SARS の被害を拡大させてしまったからです。情報公開の重要性がよく分かると思います。

司会者 角野

ありがとうございました。それでは最後に慶応大学の青木先生から海外の制度も含め、あまり会場の皆さまも伺ったこともないようなお話しと思いますので期待しております。宜しくお願いたします。

青木

慶応大学の青木と申します。宜しくお願いたします。

先程丸山先生からもお話しがありましたが、関西空港検疫所で最近、「一類感染症発生時非常対応マニュアル」を作りました。その中で、対策本部の機能として、次のような 6 つのものが挙げられています。

〈図 1〉

関西空港検疫所「一類感染症発生時非常対応マニュアル」

対策本部 関空への重大な感染症侵入危機に際して所長が臨時に設置する。

機能

- 1 情報の集約・整理・分析
- 2 特別の検疫等の対策の検討・決定
- 3 厚生労働本省への報告、支援要請
- 4 関係機関との連絡調整
- 5 広報・報道
- 6 記録作成

特にその中の 5 番目の、「広報・報道」の留意点ということで、マニュアルでは基本的スタンスとして 4 点挙げています。3 の人権への配慮は重要な点なのですが、やはり運用する時には、一層明確な指針が必要になってくると思います。

〈図 2〉

5 「広報・報道」の留意点

マニュアルの基本的スタンス

- 1 報道機関は正しい知識と事実を公開する手段である。
- 2 誠意をもって、迅速に正確な情報を提供することで、信頼関係を保持する。
- 3 個人情報や人権等に最大限に配慮する。
- 4 検疫所業務を離れた情報提供を慎む。

同じくマニュアルに「情報提供体制」として4つの指針が規定されています。これは、従来から一歩踏みだした重要な指摘がなされていると思いますが、やはり実際の運用にあたっては、例えば「定期的」とはどの程度の頻度をいうのか、スケジュールはどう作っていくのか等、細則をもっと明確にしておかないと適切な運用は難しいところがあるかと思えます。

〈図 3〉

情報提供体制

- 1 対策本部の一斉記者会見が原則
- 2 定期的発表
- 3 できれば次回発表時間等スケジュールの明確化
- 4 個別取材への対応は記録にとり、次回の発表に生かす等により、報道機関への情報は、公平に行う。

もちろんマニュアルでここまで作成したことはすごいことだとは思いますが、たとえばⅢやⅣの検疫や消毒では、手順が具体的かつ非常に詳細に書かれており、運用に迷いが生じないようになっています。これに対してⅡの対策本部中の情報提供体制は抽象的な記述にとどまって

おり、運用時に適宜判断し決定しなければならないことが多くなります。この違いはなぜ生じるのかというと、検疫や消毒は感染症法や検疫法があるのでそれに基づいて行動することができるのに対し、情報提供についての枠組みは法的に整備されていないことによります。ところで、広域感染症発生を含めて、危機発生時の情報提供体制を整備するのは、国が行うべき危機管理、安全保障の任務です。一検疫所がマニュアルで整備できる問題ではありません。国が平時から、情報提供の仕方、通信手段の確保も含めて、危機管理のガイドラインを作っておくことが必要です。感染症については、国立感染症研究所になるのか、厚生労働省になるのかは分かりませんが、どこかの機関に強制力を伴う執行権限を与え、必要な場合には準司法的な権限も与えて、情報提供がスムーズに行くように準備しておくことが求められています。カナダと日本が「人間の安全保障」を国家政策としていることを表明していますが、そのような観点からも新興・再興感染症に対する具体的なガイドラインを作ることが必要とされていると思います。

〈図 4〉

マニュアル情報提供体制の特色

- I 初動
- II 対策本部
- III 検疫
- IV 消毒

III、IVは具体的で何をすべきか明確
IIの「対策本部」中に記載の情報提供心得は抽象的

ところでアメリカはどのようなことをしているかということですが、同時多発テロ以前からCDCでは、バイオテロ、ケミカルテロその他のテロリズムに対する詳細な対応ガイドラインを作っていました。

〈図 5〉

**米国疾病管理センター(CDC)
バイオテロ対応ガイドライン**

2000年4月作成 5つの重点領域

- 1 準備・予防
- 2 検知およびサーベイランス
- 3 生物剤種類の同定・病原性等特徴把握
- 4 対処
- 5 通信システム

米国は、「9.11」を経て、愛国者法も含めて、いくつかの危機管理の法律を制定しましたが、2002年に天然痘対処ガイドラインを作りました。これは2回改正されています。改正された新しいものは「通信計画・活動」です。これも詳細に規定されています。

〈図 6〉

2002年天然痘対処ガイドライン

- 1 サーベイランス
- 2 ワクチン
- 3 隔離、検疫
- 4 検体収集および輸送
- 5 通信計画・活動
- 6 除洗

このガイドラインでは、公衆や保健従事者、マスメディアにどのような形で情報を提供するの

か、あまりにも画一的と思われるほど、現場の裁量の余地が全くないほどかつちりと手続きを決めています。その際の注目点としては、伝達的手段としてウェブを中心とすると考えていることです。それは次のような利点によります。

〈図 7〉

5 通信計画・活動

改正版 全18頁

公衆、保健従事者、マスメディアに迅速、正確かつ一貫性のある情報を提供する詳細な具体策を記す。(各部署の要員人数や電話回線数まで規定)

注目点 準備としてのweb作成(想定質問への回答は作成可能)→公衆への情報提供はwebが中心

インターネットシステムの利点として、次のようなことを挙げています。これについては、私の同僚である慶応大学の中村修先生が、厚生労働省の研究の一端としてインフルエンザのサーベイランスについて、専用線ではなく一般のインターネットで実験してみたことがあるのですが、非常に安価でありながら上手く行ったそうです。ただ、中村先生がおっしゃるには、留意すべきなのは、どのようにリンクを張るかということだそうです。信憑性が大事ですから、官邸のホームページからにするのか、厚生労働省のホームページからにするのか、いずれにせよ、情報源が信憑性のあるものであることを表示しなければなりません。中村先生は、情報の提供者を明示し、情報の信憑性がどのくらいあるのかということも明確に書き、訂正情報がある時にはきちんと訂正し、なるべく正確な良い情報をだすことが必要であるとしています。そして政府が知っていることは原則として全て出

すことが必要であり、知らないことは分らないと記載することが必要であるとしています。ただ、アメリカの場合と違い日本では、国民の間のデジタル・ディバイドの問題が現状ではあるかと思えます。

今、日本では、測位、通信と放送を一体化する、準天頂衛星を打ち上げて、また高速インターネット用衛星を打ち上げて急速に全国をブロードバンド化しようとする計画があります。したがって、日本ではアメリカと状況が違うとあきらめるよりも、日本もウェブというものを中心に考えていく、情報提供の中心的な手段とすべく検討してみることもそろそろ必要なのではないかと思えます。

〈図 8〉

インターネットシステムの利点

- 1 時刻、紙幅の制限なく大量情報伝達可能
- 2 アップデートが容易 (1日2回程度)
- 3 FAQの利便性
- 4 専用線は不要→安価

留意すべきなのは、リンクの貼り方(官邸HPから? 厚生労働省HPから?)、情報の信憑性の表示 訂正情報の扱い等より根本的にはデジタル・ディバイド

図 9にあるのは関連する最近の米国法制です。同時多発テロ以降、次のような法律が作られました。各法律では、情報提供についてどのようになるのかということを書いています。また関係する保健従事者を、医療過誤の訴訟から守るための詳細な規定も天然痘緊急要員保護法に定められています。

〈図 9〉

関連する最近の米国法令

- * 2001 12. 緊急衛生モデル州法
- * 2002 11. 国土安全保障法
- * 2003 4. 大統領令13295 (SARSを届出感染症とし、連邦法による隔離や検疫が可能な重篤な伝染病に指定)
- * 2003 5. 天然痘緊急要員保護法

感染症拡大防止措置と人権との関係に関して、2つの国や地域についての例を挙げます。香港政府では SARS の発生以降、布告を改正して、公衆衛生上感染症防止に必要な時には、差別もあり得るのだということを感じて差別布告に規定しています。但し、全てについてそうであることではなく、エイズ患者に対しては差別許容は適用しないという留保条項はキチッとつけています。

〈図 10〉

情報と人権に関する他国の例

- * 特別行政地区香港政府
- 1995年 廃疾差別布告公布
- 2003年3月 同布告改正
- 第61条
- (1) 感染症患者に対する差別は、公衆衛生防止に必要なときは、廃疾差別布告の適用除外
- (2) エイズには(1)を適用しない。

英国の例でも自由権の制限の理由の1つとして、感染症の拡大防止のために行う停留を入れ、法律の下にある命令で、停留がどういう場合にどう行われるのかということを決めています。人権と公益の調整については、必ずしも法律や

規則を作ったから、より良く機能するというわけではないのですが、諸外国の例を参考にしながら、日本の状況に合った形で、今、日本が安全保障をどういう風に考えるのかということも含めて、検討していくことが必要とされているのではないかと思います。

〈図 11〉

英国の例

1988年 人権法

第5条 自由権制限事由 の1つとして

(e)感染症の拡大防止のために行う停留
が規定

2001年 停留センター(特定疾病)命令

33の疾病指定



久保 訓子

現 職：香川県小豆保健所長
生 年：1956
最終学歴：自治医科大学
専門分野：公衆衛生




丹野 瑛喜子

現 職：埼玉県衛生研究所長
生 年：1947
最終学歴：東京慈恵会医科大学
専門分野：公衆衛生



岡部 信彦

現 職：国立感染症研究所 感染症情報センター長
生 年：1946
最終学歴：東京慈恵会医科大学
専門分野：小児科学、感染症学、感染症サーベイランス



吉澤 浩司

現 職：広島大学大学院医歯薬学総合研究科 教授
生 年：1944
最終学歴：金沢大学医学部
専門分野：肝炎ウイルス感染の疫学



木村 良一

現 職：産経新聞社 東京本社 社会部
生 年：1956
最終学歴：慶応義塾大学文学部
専門分野：医療問題、経済事件、航空事故



青木 節子

現 職：慶応義塾大学総合政策学部 助教授
生 年：1959
最終学歴：カナダ マッギル大学法学部附属
航空・宇宙法研究所博士課程
専門分野：国際法、宇宙法

ORIGINAL ARTICLE

Yasushi Ohkusa · Kiyosu Taniguchi · Ichiro Okubo

Prediction of smallpox outbreak and evaluation of control-measure policy in Japan, using a mathematical model

Received: August 26, 2004 / Accepted: January 19, 2005

Abstract Since the September 11 terrorist attacks and moreover, since the anthrax exposure events in 2001 in the United States, bioterrorism attacks seem to be a real threat. Of course, the public health authorities in Japan have started to prepare control measures for such events. We report here our attempts, using a mathematical model, to estimate outbreak size and to examine the most effective measures; comparing ring vaccination (contact tracing, isolation, and vaccination among contacts) and mass vaccination of the susceptible population in the area. The basic framework of the mathematical model follows a model used in previous research. The initial susceptible population is assumed to be 30 million persons. Concerning the important parameters, such as the number of initial-exposure cases, R_0 (infectious power, or natural history) and, the starting day of intervention after the initial exposure, we checked the robustness of our conclusions by sensitivity analysis. We found that mass vaccination is preferable to ring vaccination when the values for the initial-exposure cases and R_0 are high and when the start of intervention by public health authorities is delayed. In the base-case situation, the mass vaccination strategy needs almost 30 million vaccine doses. On the other hand, though ring vaccination needs fewer doses, it needs fewer than 50 000 doses in the worst-case scenario, that with larger first exposure, higher R_0 , or later start of public health authority intervention. This mathematical model can measure the prevalence of an infectious disease and can evaluate control measures for it before an outbreak. Especially, it is useful for the planning of the outbreaks of emerging diseases such as severe acute respiratory syndrome (SARS) or for bioterrorism attacks involving such diseases as smallpox. In further research, we will have to take into account the population people vaccinated of for smallpox, who account for about 70% of the total population in Japan.

Key words Smallpox · Vaccination · Mathematical model

Introduction

Since the September 11 terrorist attacks and, moreover, since the anthrax exposure events in 2001 in the United States, bioterrorism attacks seem to be a real threat. Of course, the public health authorities in Japan have started to prepare control measures for such events. It is very well known that a mathematical model is very useful for predicting the likelihood of a disease outbreak and for evaluating control-measure planning by a public health authority, and for evaluation of these measures after an outbreak.

Mathematical modeling is widely used in planning for responses to a pandemic,¹ and in the evaluation of control measures against severe acute respiratory syndrome (SARS),² and in the evaluation of vaccination policies.^{3,4} Especially, it is also widely used in planning responses to bioterrorism attacks in which smallpox could be used.⁵⁻⁸

By using a mathematical model, we tried to estimate outbreak size (i.e. total number of patients, outbreak duration, peak of the outbreak, and so on) and to examine the most effective measures, comparing ring vaccination (contact tracing, isolation, and vaccination among contacts) and mass vaccination of the susceptible population in the area. We report our findings here. This issue is somewhat controversial, i.e., one study found that mass vaccination was more effective,⁷ while, on the contrary, another study concluded that ring vaccination was preferable.⁸

However, these studies did not take into account the human resources limitations of the public health authorities, whereas, on the other hand, a theoretical model for HIV has considered this viewpoint explicitly.⁹ However, this model ignored the deaths due to HIV, and thus, we cannot extend the model to smallpox. In this article, we report our model, in which we tried to take into account the human resources limitations of public health authorities for


Y. Ohkusa (✉) · K. Taniguchi · I. Okubo
National Institution of Infectious Disease, 1-23-1 Toyama, Shinjuku-ku, 162-8640 Tokyo, Japan
Tel. +81-3-5285-1111 (ext., 2057); Fax +81-3-5285-1129
e-mail: ohkusa@nih.go.jp

Table 1. Base case setting

Parameters	Setting	Sources
Model	Markov	Previous research ⁵⁻⁸
R_0^a	1.5	Previous research ⁵
Duration of incubation period ^b	5-17	Previous research ⁵
Duration of prodromal period	2-3	Previous research ⁵
Duration of symptomatic period	11-15	Previous research ⁵
Number of initial-exposure cases	1	Previous research ⁷
Size of initially susceptible population	30 Million	Previous research ¹⁰
Mass vaccination		
Number of public health workers	5000	Previous research ⁷
Number of vaccination shots processed per day per public health worker	200	Previous research ⁷
Ring vaccination		
Number of contacts	50	Previous research ⁷
Maximum quarantine rate per day in the symptomatic period	0.5	Previous research ⁵
Number of vaccination shots processed per day per public health worker	200	Assumption

^a R_0 distribution follows data in previous research^{5,11}

^b The durations of the incubation, prodromal, and symptomatic periods are according to previous research⁵

Fig. 1. Natural history of smallpox

dealing with smallpox. There is no report of this kind of research with mathematical models of control measures, (namely, mass or ring vaccination) for smallpox in Japan (S. Tokuraga: The research for technological foundation from the viewpoint of precautionary medicine [unpublished manuscript]; 2003). In this sense, this study could contribute to public health policy for the preparation of measures to deal with bioterrorism attacks using smallpox.

Materials and methods

Basic structure of the model

Some assumptions in the basic structure of the model are summarized in Table 1. We adopted the Markov model setting, following previous research,⁵⁻⁸ and the epidemiological characteristics, such as R_0 (infectious power, or natural history), were borrowed from previous research,⁵ the natural history of smallpox is shown in Fig. 1. In particular, we have assumed that the value for infectious power, R_0 , as in an actual case¹⁰ is 1.5, and that it is distributed potentially in the prodromal and mainly in the symptomatic period, previously reported.^{5,10} We also assume that the incubation

period lasts for 5 to 17 days, the prodromal period lasts for 2 to 3 days, and the symptomatic period lasts for 11 to 15 days, as in the base case. R_0 is the most commonly used and important number for infection control and is defined by the basic reproduction number (which means the number of persons who are infected from one patient if all the persons are susceptible). We have used the value of $R_0 = 1.5$, for the distribution of infectiousness, incubation, prodromal, or symptomatic period over each duration from the previous research.⁵

We have also assumed, as in the previous research, that there is one initial-exposure case, and we assume that the initial susceptible population is 30 million persons, that is, the total number of the population who were born after 1976, when vaccination for smallpox had ceased (S. Tokuraga: The research for technological foundation from the viewpoint of precautionary medicine [unpublished manuscript]; 2003).

Two control measures, mass and ring vaccination, are outlined in Figs. 2 and 3, respectively. Mass vaccination is performed by 5000 public health workers and each public health worker can process 200 vaccine shots per day.⁷ On the other hand, patients can be in contact with 200 persons per day until isolation, even if they are not infected. However, among 200 persons, the number of potential

Fig. 2. Mass vaccination





Fig. 3. Ring vaccination



susceptibles who were born after 1976 is just 50 persons. This contact number seems high, although it has been used in previous research.⁷ In fact, in the episode in which a SARS-infected tourist visited Japan,¹¹ the public health authority had traced more than 200 contacts per day. Therefore 200 contacts per day seems to be a somewhat moderate number in our experience.

In the ring vaccination, 200 vaccine shots can be performed per day per public health worker, but the workers have to trace the contacts. Because tracing probably needs more human resources than these required for vaccine shots only, we assume that each public health worker can trace two persons per day.

Mathematical model

The mathematical model consists of the components, shown in Figs. 1-3, and the equations shown in the Appendix.

Several population types are summarized in the Table in the Appendix. It is notable that, because those who recover and those who die will not again be in the susceptible population, they are identical from the model's perspective.

The non-contacted susceptible population (see Appendix) are those who do not contact with the infected population, those who contact with the infected population are removed from this category. The contacted persons are classified into four types. Namely, they must be either infected or not and either quarantined or not. Non-infected and quarantined people cannot be infected during the isolation. If they are not quarantined, they are as susceptible as non-contacted susceptible persons. The infected contacts do not have any infectious power during isolation, but if they are not quarantined, they have infectious power.

If no countermeasures are adopted. The number of newly infected persons is determined by the number of the non-isolated and infected contacts in the prodromal or symptomatic period, and R_0 multiplied by the proportion of

susceptibles in the total population ($\beta S(t)$). The symbols in parenthesis here are defined in the Appendix. We note that R_0 means the number of newly infected persons in total if contacts are all susceptible, and, thus, it is the sum of newly infected persons day by day. In other words, the number of persons newly infected from one patient is described as the product of infectious power in each stage of the prodromal or symptomatic period, and $R_0 (p_{1s}(s)R_0$ and $p_{1s}(s)R_0$). Equations for $S(t)$ (Eq. 1 in Appendix) or $I_{1n}(1, t)$, $I_{1q}(1, t)$, $I_{1g}(1, t)$ (see Appendix) contain ■■.

The process is then developed into the next stage following the transition probability ($p_1(s)$, $p_2(s)$ or $p_3(s)$), and the remainder add 1 day within each stage. For instance, patients who are in the incubation period s days after the infection move to the prodromal stage at $p_1(s)$, and remain in the incubation period at $1 - p_1(s)$. Similarly, patients who are in the symptomatic period s days after the infection move to the dead or recovery stage at $p_3(s)$ or they remain in the symptomatic period at $1 - p_3(s)$. Besides 100q percent of patients in the symptomatic period are hospitalized and quarantined every day and, thus, they lose infectious power.

In ring vaccination, the public health authorities have to trace contacts, quarantine them, and perform shot vaccinations. We assume that they conduct contact tracing and isolation first. Thus, if there are many more contacts than there are staff of the public health authority, there may be some people who are not vaccinated even though they are quarantined. If more than 10 000 contacts were to occur, the public health authority could not trace all contacts in 1 day, and, thus, some patients would not be isolated. Needless to say, this would depend on the size of the outbreak. Conversely, in mass vaccination, contact tracing is not required, and so the public health authorities can administer shots to 1 million persons per day. In Eq. ■■ in the Appendix, the number of mass vaccinations per day per worker is described and W .

In the equations, the contacts (C) multiplied by the number of newly infected persons, divided by two multiplied by the number of public health workers is the rate of contacts captured (r). If this ratio is more than 1, r is limited to 1, and the remainder, which is the number of newly infected persons minus two times the number of public health workers, and not traced on that day. Even if this ratio is smaller than 1, but close to 1, some contacts captured by the health workers may not receive a vaccine shot. Formally, the proportion of ring vaccinations per day (v) is determined by

$$v = \frac{c \times \text{number of newly infected persons}}{200 \times \left(\frac{2 \times \text{number of public health workers} - c \times \text{number of } \blacksquare\blacksquare}{c \times \text{number of } \blacksquare\blacksquare} \right)}$$

Conversely, the number of mass vaccinations per day per worker is denoted by W , which is 200 times the number of public health workers.

Table 2. Setting of intervention model

Parameters	Setting	Sources
R_0	3,5,10	Previous research ^{5-8,11}
Starting day of intervention	30,45,60	Previous research ⁵
Number of initial-exposure cases	1000	Assumption

Starting day of intervention is defined as the number of days from the day that the initial-exposure case was exposed

Outcome indicator of control measures

We focus only on the cumulative number of patients, as the indicator of the outcome of control measures. In other words, we ignore the total number of deaths, even though this would seem to have a greater impact, because this number seems to be a proportion of the cumulative number of patients. Therefore a countermeasure that can avoid more patients than an other, alternative, measure is called effective.

Sensitivity analysis

We performed sensitivity analysis of the parameters summarized in Table 2, so as to confirm the robustness of the model and to take uncertainty of the parameters into consideration. Namely, R_0 values are assumed to be 3, 5, and 10, as used in previous research,^{5-8,10} in addition to the base case. R_0 values of more than 5 were also used in previous research (S. Tokunaga: The research for technological foundation from the viewpoint of precautionary medicine [unpublished manuscript]; 2003). As an intervention parameter, the starting date is assumed to be 30, 45, and 60 days after the initial case was exposed. The number of initial-exposed cases is assumed to be 1000, as in previous research,⁵ in addition to the base case.

Results

Figure 4 shows the estimated epidemic curve, which is the number of newly infected persons, in the base case, without any intervention. On the first day, one person is infected. Then there is no new patient during the incubation period of a few days in the first case. After that, the initial case has infectious power, and there is some probability of new cases. Note that, since R_0 is 1.5, and infectiousness is distributed among more than 10 days, the probability of a new infection is less than 0.2 in the earlier stage. From that time, second or third infections occur, and the number grows exponentially. The cumulative number of patients reached 122 on the final day, day 160 (Fig. 3).

Though it is not shown in Fig. 3, the peak came 2 years after the initial case was exposed, and the total number of patients reached about 17 million. Needless to say, if some intervention policy were to be implemented the course of



Fig. 4. Number of the newly infected person (without any intervention)




Table 3. Estimated numbers of infected persons in the mass-vaccination scenario

R_0	Number of people with initial exposure	Starting day of intervention	Number of patients			Number of vaccinations
			3 Months	6 Months	1 Year	
1.5	1	30	5.64	5.65	5.65	3.00×10^7
1.5	1	45	9.02	9.07	9.07	3.00×10^7
1.5	1	60	13.1	14.0	14.0	3.00×10^7
3	1	30	23.9	23.9	23.9	3.00×10^7
3	1	45	66.9	69.1	69.1	3.00×10^7
3	1	60	156	197	197	3.00×10^7
5	1	30	98.7	100	100	3.00×10^7
5	1	45	441	481	481	3.00×10^7
5	1	60	1.47×10^3	2.31×10^3	2.31×10^3	3.00×10^7
10	1	30	1.04×10^3	1.10×10^3	1.10×10^3	3.00×10^7
10	1	45	8.68×10^3	1.12×10^4	1.12×10^4	3.00×10^7
10	1	60	4.54×10^4	1.12×10^5	1.12×10^5	2.99×10^7
1.5	1000	30	5.64×10^3	5.65×10^3	5.65×10^3	3.00×10^7
1.5	1000	45	9.01×10^3	9.07×10^3	9.07×10^3	3.00×10^7
1.5	1000	60	1.31×10^4	1.40×10^4	1.40×10^4	3.00×10^7
3	1000	30	2.38×10^4	2.39×10^4	2.39×10^4	3.00×10^7
3	1000	45	6.67×10^4	6.89×10^4	6.89×10^4	2.99×10^7
3	1000	60	1.55×10^5	1.95×10^5	1.95×10^5	2.98×10^7
5	1000	30	9.81×10^4	9.93×10^4	9.93×10^4	2.99×10^7
5	1000	45	4.30×10^5	4.66×10^5	4.66×10^5	2.95×10^7
5	1000	60	1.39×10^6	2.01×10^6	2.01×10^6	2.79×10^7
10	1000	30	9.57×10^5	1.00×10^6	1.00×10^6	2.89×10^7
10	1000	45	5.58×10^6	5.96×10^6	5.96×10^6	2.40×10^7
10	1000	60	1.54×10^7	1.60×10^7	1.60×10^7	1.38×10^7

Number of patients (3 months/6 months/1 year) indicates the estimated number of patients at 3 months, 6 months, or 1 year after the initial case was exposed

prevalence would be affected and control may be achieved by adopting appropriate countermeasures such as quarantine and vaccination.

Table 3 summarizes the results for mass vaccination. Table 4 shows the results for ring vaccination. Each Table has 24 patterns of combinations of different R_0 values, and shows the number of initial-exposure cases, and the starting date of intervention. The numbers of patients in Tables 3 and 4 indicate the estimated numbers of patients 3 months, 6 months and 1 year after the initial case was exposed, and the necessary number of vaccination shots to be given.

In general, comparing Table 3 and Table 4, the total number of patients in the ring-vaccination scenario is smaller than that in the mass vaccination scenario for all patterns. Mass vaccination needs almost 30 million vaccine doses. Conversely, the necessary number of vaccine doses for ring vaccination is much smaller than that required for mass vaccination. If there is a larger number of initial cases, higher R_0 , and later start of intervention by the public health authority, more than 24 million vaccine doses are necessary. In such a scenario, mass vaccination is preferable to ring vaccination.

Table 4. Estimated numbers of infected persons in the ring-vaccination scenario

R_0	Number of people with initial exposure	Starting day of intervention	Number of patients			Number of vaccinations
			3 Months	6 Months	1 Year	
1.5	1	30	2.30	2.30	2.30	68
1.5	1	45	4.20	4.20	4.20	101
3	1	30	3.82	3.82	3.82	140
3	1	45	11.7	11.7	11.7	395
3	1	60	34.1	34.1	34.1	1.12×10^3
5	1	30	6.21	6.21	6.21	244
5	1	45	30.6	30.6	30.6	1.15×10^3
5	1	60	147	147	147	5.52×10^3
10	1	30	14.0	14.0	14.0	549
10	1	45	143	143	143	5.47×10^3
10	1	60	1.45×10^3	1.45×10^3	1.45×10^3	5.53×10^4
1.5	1000	30	2.35×10^3	2.35×10^3	2.35×10^3	0.55×10^5
1.5	1000	45	4.35×10^3	4.35×10^3	4.35×10^3	0.98×10^5
1.5	1000	60	7.33×10^3	7.33×10^3	7.33×10^3	1.72×10^5
3	1000	30	4.34×10^3	4.34×10^3	4.34×10^3	1.64×10^5
3	1000	45	1.62×10^4	1.62×10^4	1.62×10^4	7.93×10^5
3	1000	60	6.26×10^4	6.30×10^4	6.30×10^4	3.31×10^6
5	1000	30	8.97×10^3	8.97×10^3	8.97×10^3	4.26×10^5
5	1000	45	1.04×10^5	1.05×10^5	1.05×10^5	5.58×10^6
5	1000	60	8.27×10^5	1.37×10^7	2.12×10^7	1.81×10^7
10	1000	30	1.31×10^5	2.63×10^5	2.65×10^5	1.37×10^7
10	1000	45	9.82×10^6	2.91×10^7	2.91×10^7	3.32×10^6
10	1000	60	1.98×10^7	2.92×10^7	2.92×10^7	6.91×10^5

Number of patients (3 months/6 months/1 year) indicates the estimated number of patients at 3 months, 6 months, or 1 year after the initial case was exposed

Fig. 5. Cumulative number of patients in the mass-vaccination scenario ($R_0 = 1.5$, number of initial-exposed cases = 1000)




Figure 5 illustrates the movement of the cumulative number of patients in the mass vaccination scenario where, $R_0 = 1.5$, and where the number of initial-exposure cases is 1000. It clearly shows that the total number of patients would reach 14000 if intervention was delayed. Even if the public health authority could start intervention within 30 days after the initial case was exposed, the total number of patients would exceed 5000. On the other hand, as shown in Fig. 6, ring vaccination can dramatically reduce the total number of patients. Namely, even in the worst case of delay, the total number of patients would be lower than 7000. If the public authority could start intervention within 30 days

and it adopted ring vaccination, the total number of patients may be constrained to less than 2500. Therefore, we can conclude that ring vaccination is more effective when $R_0 = 1.5$ and the number of initial-exposure cases is 1000.

Figure 7 shows such relationships in more detail. The upper areas of the declining lines indicate that for the combination of $R_0 = \blacksquare$ and number of initial-exposure cases = \blacksquare , mass vaccination is more effective than ring vaccination. The blue line indicates the combination in the scenario in which the starting date of intervention is 30 days after the initial case was exposed. The pink line and yellow line indicate the combinations for 45 and 60 days, respectively. Ob-

Fig. 6. Cumulative number of patients in the case of ring vaccination scenario ($R_0 = 1.5$, number of initial-exposed cases = 1000)





Fig. 7. Comparison of the two control measures



viously, the later the intervention starts, the wider the area on the graph would be where mass vaccination is more effective. For instance, if the R_0 value is 9 and the number of initial-exposure cases is more than ten, mass vaccination would be more effective.

Discussion

We have considered, according to a mathematical model, which control measure, mass vaccination or ring vaccination, would be more effective to contain an epidemic of smallpox. We found that, if R_0 is higher, the number of initial-exposure cases is greater, or if the starting of intervention is delayed, the probability that mass vaccination is more effective than ring vaccination rises.

These results are qualitatively consistent with those in a previous study,⁷ but, quantitatively, there are large differences. Namely, the previous research found that, even if R_0

was 1, and the number of initial-exposure cases was less than 15, or if R_0 was 1.3 and the number of initial-exposure cases was 1, mass vaccination was more effective than ring vaccination. In our results, ring vaccination was definitely more effective with these parameters. On the other hand, if R_0 is 2 and the number of initial-exposure cases is 1, our result shows that ring vaccination is more effective, whereas the previous research concluded the opposite.

These two studies (i.e., the study reported by Kaplan et al.,⁷ and our present study) share a similar model framework and parameter settings, but there is a difference between them. In their study,⁷ the difference in the numbers of vaccinations represents only the difference between mass vaccination and ring vaccination. Besides, the ratio of the number of vaccinations in the mass- and ring-vaccination scenarios was fixed, as 3:1. In other words, they⁷ assumed that the public health authorities traced and captured contacts and then administered vaccination shots, and after that, they started searching for other contacts. On the other hand, we propose that the public health authorities trace

and capture contacts and then quarantine them, and after that, they start searching for other contacts. Vaccination is performed for the quarantined contacts after all contacts have been captured, because isolation stops further infections. Of course, vaccination can reduce the probability of disease onset in the infected period but not in the incubation period. This difference between the two models expands the area of the graph (Fig. 7) where ring vaccination is more effective than mass vaccination.

We have accounted for limitations in the numbers of public health workers and for priority setting for isolation and vaccination in the scenario for ring vaccination, factors that were not taken into account in the previous research.⁷ Therefore, our model seems to be more appropriate and realistic. Moreover, the results in the previous research⁷ that mass vaccination was more effective in regard to almost all parameters seems counter-intuitive. In this sense, our results may be more reliable.

Even though the value assumed for R_0 , the number of the initial-exposure cases, and the natural history probably make sense, because these numbers have also been adopted in other studies and they depend on the biological characteristics of the virus or on the type of terrorist action, there is no evidence in Japan about the starting date of intervention, the human resources of the public health authorities, or other parameters of policy action. We have simply borrowed these parameters from previous studies in other countries and so we have assumed that there are no differences among policies or the human resources of the public health authorities between these other countries and Japan. We examined the sensitivity of the starting date of intervention, and it can be seen that it affected the epidemic curve dramatically, as shown in Figs. 5 and 6. Unfortunately, there is no official documentation of a detailed action plan in the case of a bioterrorism attack or of past experience in a similar situation. Therefore, we have to keep this point in mind when we interpret the results. We also have to emphasize that obtaining reliable parameters of policies in Japan is an important task for further studies. For instance, the experience of contact tracing, when a SARS patient visited Japan in May 2003, may provide good data for such studies.¹¹

Moreover, we also need to mention the interpretation of our findings. As we limited the total number of patients as an outcome measure, we may have ignored important aspects of countermeasures. For instance, adverse effects of vaccination,^{12,13} psychological disorders due to the isolation of contacts,¹⁴ and so on. Therefore, our conclusion, which focuses only on the number of patients, may be biased if such ignored aspects are more important than the aspects we focused on. In principle, we have to evaluate all aspects of policy in their entirety but this seems to be a very difficult task, and it may be the next necessary step in this field. At least, we remind that this conclusion reflect only total number of patients when we interpret it.

Moreover, we have to take into account the heterogeneous population distribution or spatial spread of disease

due to the movement of infected persons to evaluate movement restrictions or other control measures, even though we have considered uniform and homogenous population distribution in our model.

Moreover, if the number of vaccination doses is severely limited, we have to choose either ring vaccination or priority vaccination for medical staff and public health workers. A mathematical model could provide the answers to those questions and such a model will be one of the most important issues for the planning of measures to be taken in the event of a bioterrorism attack.

Furthermore, though we ignored about 90 million people who were born before 1976 and were vaccinated before 1980, we have to take them into account. They may keep their immunity, protecting them from infection. They may play a key role in the control measures.

Acknowledgments This research was funded by Health and Labour Science Research Grants in 2003 for Special Research, titled "Extensive Coordination among Government Offices and Medical Institutions for Large Scale Outbreak", headed by Dr. I. Okubo, Tsukuba University. We thank Mr. Kumio Tsuyuhara, Osaka University, and Ms. Tamie Sugawara, Tsukuba University, for their helpful research assistance. Needless to say, any remaining errors are ours.

References

1. van Genugten MLL, Heijnen MLA, Jager JC. Pandemic influenza and health care demand in the Netherlands: scenario analysis. *Emerg Infect Dis* 2003;9:531-8.
2. Lipsitch M, Cohen T, et al. Transmission dynamics and control of severe acute respiratory syndrome. *Science* 2003;300:1884-5.
3. Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. *Med Decis Making* 2003;23:76-82.
4. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. *JAMA* 1994;271:375-81.
5. Metzler MI, Damon I, LeDuc JW, Miller JD. Modeling potential response to smallpox as a bioterrorist weapon. *Emerg Infect Dis* 2001;7:959-69.
6. Gani R, Leach S. Transmission potential of smallpox in contemporary population. *Nature* 2001;414:748-51.
7. Kaplan EH, Craft DL, Wein LM. Emergency response to a smallpox attack: the case for mass vaccination. *Proc Natl Acad Sci U S A* 2003;100:4346-51.
8. Halloran ME, Longini IM Jr., Nizam N, Yang Y. Containing bioterrorist smallpox. *Science* 2002;298:1428-32.
9. Brandeau ML, Zanic GS, Richter A. Resource allocation for control of infectious disease in multiple independent populations: beyond cost-effectiveness analysis. *J Health Econ* 2003;22:575-98.
10. Meack TM. Smallpox in Europe, 1950-1971. *J Infect Dis* 1972;125:161-9.
11. Taiwan tourist diagnosed with SARS in Japan. <http://cnews.canoe.ca/CNEWS/World/2003/06-26/119688-ap.html>. Canadian Press; 2003.
12. Thorpe LE, Mostashari F, Karpati AM, Schwartz SP, Manning SE, Marx MA, et al. Smallpox vaccination and cardiac deaths, New York City, 1947. *Emerg Infect Dis* 2004;10:917-20.
13. Meltzer M. Risks and benefits of preexposure and postexposure smallpox vaccination. *Emerg Infect Dis* 2003;9:1363-70.
14. Hawryluck L, Gold WL, Robinson S, Pogorski S, Galea S, Styra R. SARS control and psychological effects of quarantine, Toronto, Canada. *Emerg Infect Dis* 2004;10:1206-12.

Appendix

Classification of population	Symbol
Non-contacted susceptible (unvaccinated)	$S(t)$
Non-contacted susceptible (vaccinated)	$S_v(t)$
Recovered or dead	$D(t)$
Non-infected contacts quarantined (vaccinated)	$S_{qv}(s,t)$
Non-infected contacts quarantined (unvaccinated)	$S_q(s,t)$
Non-infected contacts unquarantined (susceptible)	$S_n(s,t)$
Infected contacts unquarantined in incubation period	$I_{1n}(s,t)$
Infected contacts unquarantined in prodromal period	$I_{2n}(s,t)$
Infected contacts unquarantined in symptomatic period	$I_{3n}(s,t)$
Infected contacts quarantined in incubation period who are vaccinated	$I_{1qv}(s,t)$
Infected contacts quarantined in incubation period who are not vaccinated	$I_{1q}(s,t)$
Infected contacts isolated in prodromal period	$I_{2q}(s,t)$
Infected contacts isolated in symptomatic period	$I_{3q}(s,t)$
R_0 /population	β
Distribution of infectiousness in day s of prodromal period	$p_{1s}(s)$
Distribution of infectiousness in day s of symptomatic period	$p_{2s}(s)$
Probability of transition from day s of incubation period to prodromal	$p_1(s)$
Probability of transition from day s of prodromal period to symptomatic	$p_2(s)$
Probability of transition from day s of symptomatic period to death or recovery	$p_3(s)$
Rate of ring vaccinations per day	ν
Number of mass vaccinations per day per worker	W
Number of contacts per day	C
Rate of infected persons captured	q
Rate of contacts captured	r

Transition of non-contacted unvaccinated susceptible persons

$$S(t) = \left(1 - \sum_{s=1}^{N_1} p_{1s}(s) \beta I_{2n}(s, t-1)\right) S(t-1) - C \sum_{s=1}^{N_1} I_{2n}(s, t) \quad (1)$$

$$+ (1-r) \left(1 - \beta \left(\sum_{s=1}^{N_1} p_{1s}(s) I_{2n}(s, t-1) + \sum_{s=1}^{N_1} p_{1s}(s, t-1)\right)\right) S_n(N_1 + N_2, t) \\ + S_{qv}(N_1 + N_2, t-1) - W + S_q(N_1 + N_2, t-1) \quad (2)$$

Transition of those who recover or die

$$D(t) = D(t-1) + (1-r)(1-q) \sum_{s=1}^{N_1} p_3(s) I_{3n}(s, t-1) + \sum_{s=1}^{N_1} p_3(s) I_{3q}(s, t-1) \quad (3)$$

Transition of non-infected quarantined contacts who are vaccinated

$$S_{qv}(1, t) = \nu \sum_{s=1}^{N_1} r q \left(C - p_{1s}(s) \beta S(t-1)\right) \quad (4)$$

$$+ \sum_{j=1}^{N_1+N_2} S_n(j, t-1) \Big) I_{3n}(s, t-1) + r \sum_{s=1}^{N_1} S_n(s, t-1) \quad (5)$$

$$S_{qv}(s, t) = S_{qv}(s-1, t-1) + e I_{1qv}(s-1, t-1) + \nu S_q(s-1, t-1) \quad (s=2, \dots, N_1) \quad (6)$$

(7)

Transition of non-infected unquarantined contacts who are susceptible

$$S_n(1, t) = \sum_{s=1}^{N_1} (1-rq) \left(C - p_{1s}(s) \beta S(t-1)\right) + \sum_{s=1}^{N_1+N_2} S_n(i, t-1) \Big) I_{3n}(s, t-1) \quad (8)$$

$$S_n(s, t) = (1-r) \left(1 - \beta \left(\sum_{i=1}^{N_1} p_{1i}(i) I_{2n}(i, t-1) + \sum_{i=1}^{N_1} p_{1i} I_{3n}(i, t-1)\right)\right) S_n(s-1, t-1) \quad (s=2, \dots, N_1) \quad (9)$$

Transition of infected contacts, quarantined in incubation period, who are vaccinated

$$I_{1qv}(1, t) = r q \nu \beta \left(S(t-1) + \sum_{s=1}^{N_1+N_2} S_n(i, t-1)\right) \sum_{s=1}^{N_1} p_{1s} I_{3n}(j, t-1) + r I_{1n}(1, t-1) \quad (10)$$

$$I_{1qv}(s, t) = (1-p_1(s-1))(1-e_\nu) I_{1qv}(s-1, t-1) + r I_{1n}(s-1, t-1) \\ + (1-p_1(s-1)) \nu I_{1q}(s-1, t-1) \quad (s=2, \dots, N_1) \quad (11)$$

Transition of infected contacts who are not quarantined in incubation period

$$I_{1n}(1,t) = (1-r)\beta \sum_{j=1}^{N_1} \left(\sum_{i=1}^{N_2} p_{I_2}(i-1) I_{2n}(i-1,t-1) \right) + \sum_{i=1}^{N_1} p_{I_1}(i-1) I_{3n}(i-1,t-1) S_n(j,t-1) \\ + (1-qr) \sum_{j=1}^{N_1} p_{I_3}(j) \beta \left(S(t-1) + \sum_{i=1}^{N_1+N_2} S_n(i,t-1) \right) I_{3n}(j,t-1) + \beta p_{I_1} I_{2n}(i,t-1) S(t-1) \quad (12)$$

$$I_{1n}(s,t) = (1-r)(1-p_1(s-1)) I_{1n}(s-1,t-1) \quad (s=2, \dots, N_1) \quad (13)$$

Transition of infected contacts who are not isolated in prodromal period

$$I_{2n}(1,t) = (1-r) \sum_{i=1}^{N_1} p_1(i) I_{1n}(i,t-1) \quad (14)$$

$$I_{2n}(2,t) = (1-r)(1-p_2(1)) I_{2n}(1,t-1) \quad (15)$$

Transition of infected contacts who are not isolated in symptomatic period

$$I_{3n}(1,t) = (1-r) \sum_{i=1}^{N_2} p_2(i) I_{2n}(i,t-1) \quad (16)$$

$$I_{3n}(s,t) = (1-r)(1-q)(1-p_3(s)) I_{3n}(s-1,t-1) \quad (s=2, \dots, N_2) \quad (17)$$

Transition of non-infected quarantined contacts who are not vaccinated

$$S_q(1,t) = (1-\nu)r q \sum_{i=1}^{N_1} \left(C - \beta p_{I_1}(i) (S(t-1) + \sum_{j=1}^{N_1+N_2} S_n(j,t-1)) \right) I_{3n}(i,t-1) \quad (18)$$

$$S_q(s,t) = (1-\nu) S_q(s-1,t-1) \quad (s=2, \dots, N_1) \quad (19)$$

Transition of infected contacts, quarantined in incubation period, who are not vaccinated

$$I_{1q}(1,t) = (1-\nu)r q \beta \sum_{i=1}^{N_1} p_{I_1}(i) \left(S(t-1) + \sum_{j=1}^{N_1+N_2} S_n(j,t-1) \right) I_{3n}(i,t-1) \quad (20)$$

$$I_{1q}(s,t) = (1-p_1(s))(1-\nu) I_{1q}(s-1,t-1) \quad (s=2, \dots, N_1) \quad (21)$$

Transition of infected contacts isolated in prodromal period

$$I_{2q}(1,t) = \sum_{i=1}^{N_1} p_{I_1}(i) (1-\nu) I_{1q}(i,t-1) \quad (22)$$

$$I_{2q}(2,t) = (1-p_2(1))(1-\nu) I_{2q}(1,t-1) \quad (23)$$

Transition of infected contacts isolated in symptomatic period

$$I_{3q}(1,t) = \sum_{i=1}^{N_2} p_2(i) I_{2q}(i,t-1) + r \sum_{i=1}^{N_2} p_2(i) I_{2n}(i,t-1) \quad (24)$$

$$I_{3q}(s,t) = (1-(1-r)(1-q)) I_{3n}(s-1,t-1) + (1-p_3(s-1)) I_{3q}(s-1,t-1) \quad (s=2, \dots, N_2) \quad (25)$$

Transition of non-contacted susceptible persons who are vaccinated in mass-vaccination scenario

$$S_v(t) = W + S_v(t-1) \quad (26)$$

内部資料用



パークランド
保健／病院システム

NBC 準備ガイドライン

2000年9月

(日本語翻訳 Nov. 2003 Ver.2c)